"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Concept/Terms
Alendronate- Alendronate
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in Harvard Catalyst Profiles by year, and whether "Alendronate" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 3 | 4 |
| 1999 | 3 | 0 | 3 |
| 2000 | 4 | 5 | 9 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 6 | 1 | 7 |
| 2004 | 3 | 0 | 3 |
| 2005 | 4 | 2 | 6 |
| 2006 | 4 | 1 | 5 |
| 2007 | 3 | 1 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 5 | 4 | 9 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 5 | 3 | 8 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 3 | 5 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 2 | 2 |
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Bone Miner Res. 2022 11; 37(11):2351-2372.
-
Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022 Jun; 33(6):1243-1256.
-
AGN1 implant material to treat bone loss: Resorbable implant forms normal bone with and without alendronate in a canine critical size humeral defect model. Bone. 2022 01; 154:116246.
-
Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J Exp Med. 2021 12 06; 218(12).
-
The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: A post-hoc HR-pQCT study. Bone. 2022 01; 154:116187.
-
Microsphere embedded hydrogel construct - binary delivery of alendronate and BMP-2 for superior bone regeneration. J Mater Chem B. 2021 09 14; 9(34):6856-6869.
-
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. J Gen Intern Med. 2022 06; 37(8):1917-1924.
-
Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age. Clin Infect Dis. 2021 03 15; 72(6):1059-1063.
-
Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial. Osteoporos Int. 2021 Jan; 32(1):55-61.
-
Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clin Infect Dis. 2020 08 22; 71(5):1281-1288.